Skip Navigation

Masks Strongly Recommended but Not Required in Maryland, Starting Immediately

Due to the downward trend in respiratory viruses in Maryland, masking is no longer required but remains strongly recommended in Johns Hopkins Medicine clinical locations in Maryland. Read more.

Find a Doctor

Find a Researcher

Jun Luo, Ph.D.

Headshot of Jun Luo
  • Alan W. Partin, M.D., Ph.D. Professor in Urology
  • Professor of Urology

Research Interests

Prostate cancer genomes; Prostate tumor biology; Prostate cancer ...read more

Background

Dr. Jun Luo is the Alan W. Partin, M.D., Ph.D. Professor in Urology at the Johns Hopkins School of Medicine. His research focuses on prostate cancer biology, genetics/genomics, detection, and treatment.

Dr. Luo received his B.S. in zoology from Nanjing University in 1990, and completed a Ph.D. in anatomy and cell biology at the University of Iowa in 1999. He then completed a postdoctoral fellowship in oncogenomics at Johns Hopkins University in 2002 and joined the Johns Hopkins staff that same year.

Dr. Luo holds multiple patents for discoveries that assist in the detection and treatment of prostate cancer. He has published extensively, and has won numerous awards for his scholarship and research. He is a member of the American Association for Cancer Research, American Urological Association, American Society of Clinical Oncology, and the Society for Basic Urologic Research.

...read more

Titles

  • Alan W. Partin, M.D., Ph.D. Professor in Urology
  • Professor of Urology
  • Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • B.S.; Nanjing University (China) (1990)
  • Ph.D.; University of Iowa (Iowa) (1999)

Additional Training

  • the Johns Hopkins University, Baltimore, MD, 2002, Oncogenomics

Research & Publications

Research Summary

Dr. Luo’s research focuses on genomic studies of prostate cancer. His research interests include the discovery, validation and application of molecular determinants and indicators of prostate cancer progression in various treatment settings. He is also interested in prostate tumor biology and genomic research to explain the substantial variation in prostate cancer incidence and mortality rates among different geographic regions and racial/ethnic groups.

Selected Publications

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England journal of medicine. 2014;371(11):1028-38. Epub 2014/09/04. doi: 10.1056/NEJMoa1315815. PubMed PMID: 25184630.

Ferraldeschi R, Welti J, Luo J, Attard G, de Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene. 2014. Epub 2014/05/20. doi: 10.1038/onc.2014.115. PubMed PMID: 24837363.

Nakazawa M, Antonarakis ES, Luo J. Androgen receptor splice variants in the era of enzalutamide and abiraterone. Hormones & cancer. 2014;5(5):265-73. Epub 2014/07/23. doi: 10.1007/s12672-014-0190-1. PubMed PMID: 25048254; PubMed Central PMCID: PMC4167475.

Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. Journal of cellular biochemistry. 2014;115(9):1505-15. Epub 2014/03/08. doi: 10.1002/jcb.24805. PubMed PMID: 24604720.

Aryee MJ, Liu W, Engelmann JC, Nuhn P, Gurel M, Haffner MC, Esopi D, Irizarry RA, Getzenberg RH, Nelson WG, Luo J, Xu J, Isaacs WB, Bova GS, Yegnasubramanian S. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Science translational medicine. 2013;5(169):169ra10. Epub 2013/01/25. doi: 10.1126/scitranslmed.3005211. PubMed PMID: 23345608; PubMed Central PMCID: PMC3577373.

Patents

Composition and methods for treating and preventing prostate cancer and for detecting androgen receptor variants.
Patent # P10305-02 | 

Methods of detecting prostate cancer.
Patent # 60/959,954 | 

Contact for Research Inquiries

600 N Wolf St.
411 Marburg Building
Baltimore, MD 21287-2101 map
Phone: 443-287-5625

Email me

Activities & Honors

Honors

  • Phyllis and Brian L. Harvey Scholar, 2007
  • David H. Koch Foundation Award, 2006
  • Pathology Young Investigators' Day Award for Excellence in Basic Science Research, Department of Pathology, Johns Hopkins University School of Medicine, 2002
  • Scholar-in-Training Award, American Association for Cancer Research, 2001
  • Young Investigator Award, American Association for Cancer Research, 1999
  • Tung-Yang Wing Award for Superior Achievement, Department of Anatomy and Cell Biology, University of Iowa, 1998

Memberships

  • American Association for Cancer Research, 1999
Is this you? Edit Profile
back to top button